Search results
Showing 1 to 6 of 6 results for ovulation
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.
Show all sections
Sections for NG257
- Overview
- Principles of care
- Initial advice to people concerned about delays in conception
- Advice about factors that can affect fertility
- Defining infertility and initial assessment
- Investigation of fertility problems and management strategies
- Management of male factor fertility problems
- Management of female factor fertility problems
Long-term safety of ovarian stimulation and ovulation induction for women:- Is there an association between ovulation...
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain (HTG150)
Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain. This involves the destruction of a small segment of ligament that carries nerve fibres within the pelvis.
View recommendations for HTG150Show all sections
Sections for HTG150
This quality standard covers assessing and treating fertility problems in people with explained and unexplained infertility, including access to IVF treatment. It also covers cryopreservation before cancer treatment that may affect fertility. It describes high-quality care in priority areas for improvement.
View quality statements for QS73Show all sections
Sections for QS73
- List of quality statements
- Quality statement 1: Lifestyle advice
- Quality statement 2: Referral for specialist consultation
- Quality statement 3: Counselling
- Quality statement 4: Semen analysis
- Quality statement 5: IVF for women, trans men and non-binary people with female reproductive organs aged under 40 years
- Quality statement 6: IVF for women, trans men and non-binary people with female reproductive organs aged 40 or 41 years
- Quality statement 7: Intracytoplasmic sperm injection